Your contact person
Manager PR & Communications Jan Phillip Denkers
Life Science Nord takes stock of a positive BIO-Europe in Hamburg
The North German cluster management Life Science Nord is more than happy with the results of the international Biotech pharmaceuticals conference that took place ...
Evotec SE: Results and corporate updates
Evotec SE reported financial results and corporate updates for the first nine months ended 30 September 2019. VERY STRONG FINANCIAL PERFORMANCE Group revenues: 16% increase ...
Evotec and Vifor Pharma form joint venture for early development in nephrology
Evotec SE and Vifor Pharma announced the launch of a 50:50 joint venture focused on the discovery and development of novel nephrology therapeutics. Vifor ...
Read more …
BIO-Europe: The countdown has begun
Preparations for Europe’s leading conference for the biotech and pharmaceutical industry are entering the crucial stage: Next week, from November 11-13, BIO-Europe will be ...
Evotec and Celmatix enter into strategic collaboration
Evotec SE and Celmatix Inc., a precision medicine company with a proprietary multi-omics platform, announced a partnership to develop pre-clinical programmes in prevalent but ...
Evotec reaches milestone in integrated drug discovery and development partnership with Aeovian
Evotec SE announced that the Company has reached a milestone in a drug discovery and development partnership with the biopharmaceutical company Aeovian Pharmaceuticals, Inc. ...
Evotec and Indivumed achieve milestone in joint strategic drug discovery collaboration
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) and Indivumed GmbH announced that the first milestone has been successfully achieved in their joint ...
Evotec and Takeda enter collaboration
Evotec SE announced a strategic, multi-year drug discovery collaboration with Takeda Pharmaceutical Company Limited (“Takeda”). Under the collaboration, the parties aim to establish at ...
Eppendorf AG: Positive first half-year 2019
The globally active Eppendorf Group charted a strong first half-year in 2019 with a significant surge in Group sales to €378.5 million (prior year: ...
New IMI project “GNA NOW” kicks off its battle against antimicrobial resistance
Evotec SE and Lygature announced their cooperation in a new initiative for the development of novel antibacterial agents: Gram-Negative Antibacterials NOW (“GNA NOW”). The ...
Evotec expands its iPSC discovery platform
Evotec SE announced that the Company has acquired assets from the stem cell specialist Ncardia AG to advance Evotec’s iPSC platform, one of the ...
Evotec and venture capital consortium form "Breakpoint Therapeutics GmbH"
Evotec SE announced the formation of Breakpoint Therapeutics GmbH, a spin-off company focusing on the development of Evotec’s DNA damage response (“DDR”) portfolio, comprising ...